Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
60results about How to "Exert anti-tumor effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fusion protein efficiently combined with PD-1 and VEGF, and coding sequence and use thereof
The invention belongs to the biological medicine field, and relates to a fusion protein efficiently combined with a PD-1 and a VEGF, and a coding sequence and a use thereof. Specifically, the invention relates to the separated fusion protein comprising the following peptide fragments: (1) a human PD-L2 extracellular region peptide fragment; (2) a peptide fragment of a second immunoglobulin-like structural domain of a human FLT-1 extracellular region or / and a peptide fragment of a third immunoglobulin-like structural domain of a KDR extracellular region; and optionally (3) a human immunoglobulin Fc fragment. The fusion protein can inhibit the growth of tumor cells, promotes the death of the tumor cells, inhibits T cell inactivation, and enhances a tumor killing ability.
Owner:SHANGHAI ALLBRIGHT BIOTECH +1
Novel mesoporous silicon sphere co-loaded medicine nano-complex and preparation method thereof
InactiveCN108815523AReduce releaseIncrease drug concentrationOrganic active ingredientsEnergy modified materialsSuperparamagnetic iron oxide nanoparticlesMesoporous silica
The invention discloses a novel mesoporous silicon sphere co-loaded medicine nano-complex and a preparation method thereof. The novel mesoporous silicon sphere co-loaded medicine nano-complex is Ce6@MMSN / DOX / Ko143@PAsp-b-PEG-FA; the preparation method comprises the following steps: selecting TEOS (Tetraethyl Orthosilicate) as a silicon source, CTAB (Cetyltrimethyl Ammonium Bromide) as a template agent and n-hexane as a pore expanding agent and synthesizing mesoporous silicon dioxide nanoparticles with a double-pore-channel core-shell structure; carrying out amination modification on the mesoporous silicon dioxide nanoparticles; synthesizing Fe3O4 nanoparticles by adopting an LSS (Liquid-Solid-Solution) phase transfer method and ligand exchange reaction; modifying and embedding superparamagnetic iron oxide nanoparticles on the surface of aminated MSN through nucleophilic substitution, so as to construct magnetic mesoporous silicon dioxide nanoparticles; taking DCC (Dicyclollexyl Carbodiimide) as a condensation agent and covalently binding a photosensitizer Ce6 through amidation; meanwhile, loading a BCRP (Breast Cancer Resistance Protein) inhibitor Ko143; then crossly linking a copolymer FA-PEG-b-PAsp; finally, loading an anti-tumor medicine DOX.
Owner:SECOND AFFILIATED HOSPITAL SECOND MILITARY MEDICAL UNIV
N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds and application thereof
ActiveCN106279303AInhibition of catalytic activityExert anti-tumor effectOrganic active ingredientsSugar derivativesAnhydrase activityThiourea
The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.
Owner:SHENYANG PHARMA UNIVERSITY
TAT-IL-24-KDEL fusion protein as well as preparation method and application thereof
InactiveCN103755814AEffective positioningPromote apoptosisPolypeptide with localisation/targeting motifPeptide/protein ingredientsHeterologousInclusion bodies
The invention discloses a TAT-IL-24-KDEL fusion protein which is a fusion protein of which TAT cell-penetrating peptide and endoplasmic reticulum positioning signal peptide KDEL are respectively connected with the N terminal and C terminal of interleukin-24(IL-24). The preparation steps comprises: performing PCR (Polymerase Chain Reaction) amplification to obtain a TAT-IL-24-KDEL encoding gene, by using pET28-SUMO as a carrier, converting BL21(DE3), and heterologously expressing the TAT-IL-24-KDEL fusion protein with SUMO label. Because the fusion protein is expressed in a mode of inclusion body, and a high-purity TAT-IL-24-KDEL fusion protein is obtained after the operations of renaturation, nickel column purification and label removing. The TAT-IL-24-KDEL fusion protein purified through flow cell experiment detection has apoptosis-promoting action to breast cancer MCF-7 cells, and the positioning condition of the fusion protein in the cells is detected by using immunofluorescence experiment detection. The invention firstly provides a preparation method of the TAT-IL-24-KDEL fusion protein; the purity reaches 92 percent; the TAT-IL-24-KDEL fusion protein can be effectively positioned on endoplasmic reticulum to promote the apoptosis of the breast cancer MCF-7 cells.
Owner:EAST CHINA UNIV OF SCI & TECH
Chinese herbal compound preparation, and preparation method and application of Chinese herbal compound preparation
ActiveCN103520360AEffective treatmentImprove immunityRespiratory disorderAntineoplastic agentsMedicineBrain tumor
The invention relates to an anti-tumor Chinese herbal compound preparation, a Chinese herbal compound extract, and preparation methods and application of the anti-tumor Chinese herbal compound preparation and the Chinese herbal compound extract. The effective ingredients of the anti-tumor Chinese herbal compound preparation and the Chinese herbal compound extract are prepared from the following raw materials in part by weight: 5-8 parts of algae, 2-4 parts of oyster, 2-4 parts of solanum nigrum and 1-3 parts of rhizoma menispermi. The Chinese herbal compound preparation or the Chinese herbal compound extract can be used for preparing drugs for treating lung cancer, lymph cancer, liver cancer, ascitic tumor, brain tumor, glioma and the like.
Owner:OCEAN UNIV OF CHINA
In vitro expansion method for anti-tumor T cells from non-sentinel lymph nodes
ActiveCN108220234ARich in T cellsBreak through the tumor immunosuppressive effectCell dissociation methodsBlood/immune system cellsAntigenT-Cell Specificity
The invention discloses an in vitro expansion method for anti-tumor T cells from non-sentinel lymph nodes. The method comprises the following four steps: antigen-pulsed and immunosuppression blocking,T cell subset separation and excitated proliferation, reexcitation and rapid proliferation of a T cell subset, and harvesting. The in vitro expansion method has the characteristics that the activation of T cell specificity is facilitated, the anti-tumor capacity of T cells can be improved, the quantity of tumor specific T cells is increased, the operation is simple and convenient and the method is easy for popularization.
Owner:贵州太瑞生诺生物医药有限公司
Bionic magnetosome loaded with siRNA and preparation method of magnetosome
ActiveCN106039324AEfficient aggregationFast gatheringOrganic active ingredientsEnergy modified materialsPeptideMagnetosome
The invention relates to a bionic magnetosome loaded with siRNA and a preparation method of the magnetosome, and belongs to the field of chemistry and biomedicine. According to the bionic magnetosome, water-soluble MNC serves as the kernel and is wrapped by a white cell membrane, and siRNA is loaded between the MNC and the white cell membrane; antibodies or peptides with modifying groups can be coupled outside the white cell membrane of the bionic magnetosome in a covalence mode. By preparing MNC, M and MNC:siRNA and mixing an MNC:siRNA solution, an M solution and a buffer solution, the bionic magnetosome is obtained; the white cell membrane of the bionic magnetosome is modified by the peptides or antibodies through the modifying groups, and the bionic magnetosome coupled with the antibodies or peptides is obtained. The MNC in the bionic magnetosome has positive charges, can adsorb siRNA and is wrapped by M for bionics, a focus is reached efficiently and rapidly, and meanwhile immune elimination of organisms is avoided.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY +1
Application of miR-124-3p and analogues thereof in preparation of anti-breast cancer disease drugs
InactiveCN110251529APrevent proliferationInhibit migrationOrganic active ingredientsMicrobiological testing/measurementDrugWilms' tumor
The invention provides an application of miR-124-3p and analogues thereof in preparation of anti-breast cancer disease drugs. The miR-124-3p has a sequence of 5'-UAAGGCACGCGGUGAAUGCCAA-3'. Experiments prove that the expression of the miR-124-3p is significantly inhibited during the occurrence of breast cancer; with restoring of the expression of the miR-124-3p, the proliferation and migration of breast cancer cells can be inhibited by targeting adjustment of the expression of MGAT5, and thus an anti-tumor role is played. A new molecular marker is provided for diagnosis of breast cancer and a new potential molecular target is provided for clinical treatment.
Owner:SHANGHAI CHANGHAI HOSPITAL
Nanoparticle compound with tumor microenvironment responsive deformation
ActiveCN111939268AAssembly recoveryAchieve long-term therapeutic effectPowder deliveryOrganic active ingredientsCarboxylic acidPolylysine
The invention discloses a nanoparticle compound with tumor microenvironment responsive deformation. The nanoparticle compound is formed by combining an amphiphilic oligo-polypeptide drug conjugate andbeta-carboxylic acid amide polylysine through electrostatic interaction. The amphiphilic oligo-polypeptide drug conjugate is a product obtained by condensation of an anti-cancer drug adriamycin and an oligo-polypeptide KIGLFRWR through a chemical bond. The nanoparticle compound can be passively gathered at a tumor site in a targeted manner; under the acidic pH condition of a tumor region, a beta-carboxylic acid amide group connected to polylysine is broken, charge of the polylysine is changed into positive charge from negative charge, and the polylysine repels the amphiphilic oligo-polypeptide drug conjugate with positive charge, so that the nanoparticle compound is dissociated; and then the amphiphilic oligo-polypeptide drug conjugate can be further assembled into a long fiber, so that long-time retention is achieved at the tumor site, the drug adriamycin is slowly released, and the efficient anti-cancer effect is achieved.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
Preparation method and application of oyster shell extract
ActiveCN101953850AExert anti-tumor effectAntineoplastic agentsCardiovascular disorderOysterAngiogenic inhibitors
The invention relates to a preparation method of an oyster shell extract. The method comprises the following steps of: adding water-containing solution of alcohol into oyster shell powder in a material to liquid ratio of 1g:2-20mL, performing reflux extraction and filtering or centrifugally separating liquid out; and concentrating the obtained liquid under reduced pressure, extracting with an organic solvent, separating an organic solvent layer out, concentrating under reduced pressure and drying to obtain the oyster shell extract. Tests by a lissamine rhodamine B method indicate that the prepared oyster shell extract has the function of inhibiting cell proliferation of a plurality of tumor cell strains; and tests by a methyl thiazolyl tetrazolium method indicate that the oyster shell extract has the function of inhibiting cell proliferation of human umbilical vein endothelial cells. Experiments indicate that the oyster shell extract can play a role in resisting tumors by inhibiting tumor cell proliferation and angiogenesis. Therefore, the oyster shell extract of the invention can be taken as a cell proliferation inhibitor, an angiogenesis inhibitor and an anti-tumor agent.
Owner:OCEAN UNIV OF CHINA
MicroRNA (micro ribonucleic acid) for regulating gene expression of B7-H3 (a molecule of the B7 family)
The invention discloses microRNA (micro ribonucleic acid) for regulating gene expression of B7-H3 (a molecule of the B7 family). The microRNA is nucleic acid, functional segment or variant including a sequence of 5'-UGAGAUGAAGCACUGUAGCUC-3'. The microRNA is miR-143. Performed in-vitro biological function tests show that hsa-miR-143 is capable of inhibiting molecular expression of the B7-H3 by bonding with 3'-UTR (untranslated regions) of the B7-H3 gene, and antitumor effect is achieved by regulating a signal path of the B7-H3 and / or expression and functions of the miR-143.
Owner:SUZHOU UNIV
Compound Chinese medicament for treating cancer and preparation method thereof
InactiveCN102631378AAct quicklyGood effectAerosol deliveryImmunological disordersPharmaceutical formulationPharmaceutical Substances
The invention relates to a medicinal preparation and a preparation method thereof and in particular relates to a compound Chinese medicament for treating cancer and a preparation method thereof. The compound Chinese medicament for treating cancer is produced into spray and aerosol, the sprayed mist-state liquid is mixed with negative oxygen ions to both act on the nasal cavity, or directly produced into oral solution. The medicament is prepared from fermentative cordycep fungal powder and ganoderma lucidum powder at a weight ratio of 1:(0.8-1.2). The preparation method comprises the following steps: weighing the fermentative cordycep fungal powder and ganoderma lucidum powder according to the weight ratio; sealing with deionized water and heating to 80-100 DEG C, extracting for 1 hour, and filtering to obtain an extract; sealing with deionized water and heating to 80-100 DEG C, filtering to obtain an extract; combining the two extracts, heating to 80 DEG C, concentrating into a medicinal concentrated solution; and cooling to normal temperature to prepare the medicinal concentrated solution of the compound Chinese medicament for treating cancer.
Owner:邹平起 +1
A lysosome-targeted pH-sensitive nanoparticle and a preparation method and application thereof
ActiveCN109200021ASmall particle sizeGood dispersionOrganic active ingredientsPharmaceutical non-active ingredientsPh sensitive nanoparticlesLysosomal targeting
The invention relates to the technical field of biomedical technology, and discloses lysosome-targeted pH-sensitive nanoparticle, comprising adriamycin calcium complex Ca-DOX cluster formed by chelating calcium ions Ca<2+> with adriamycin DOX. Fibroin is attached to the surface of the adriamycin calcium complex Ca-DOX cluster. The invention can enable more nanoparticles to be swallowed into the lysine body by cells, the aggregation degree and effective drug loading of nanoparticles in tumor region are improved, and accelerated the decomposition of nanoparticles in lysosomes, so that more Ca<2+> and CO2 are released, adriamycin can be released from the lysosome and enter the cell nucleus to play an anti-tumor role, thus effectively improving the lethality of the tumor, achieving the effectof tumor treatment, and providing a new direction for the clinical treatment of tumor.
Owner:CHONGQING MEDICAL UNIVERSITY
Construction of high-penetrability tumor target lipid insert and effect thereof in promoting cell and cell membrane preparation to aggregate toward tumor
InactiveCN106924748AEasy to makeGood repeatabilityImmunological disordersMacromolecular non-active ingredientsTumor targetCell membrane
The invention relates to a high-penetrability tumor target lipid insert and a preparation method thereof. The insert is prepared from a high-penetrability peptide iRGD containing ingredient and DSPE-PEG-MAL, and can be inserted onto a plurality of drug-loaded systems and cells to realize active tumor target. According to the preparation method, the substance of the high-penetrability peptide iRGD containing ingredient serving as a molecule for realizing tumor active target and high penetrability is used for modifying a segment of lipid molecules to form a multi-functional tumor target insert capable of definitely reinforcing tumor target. Repeated experiments after successful construction verify that the tumor target lipid insert has definite tumor targeting and can be used for actually reinforcing tumor local aggregation of cell and cell membrane preparations and improving the anti-tumor treatment effect.
Owner:NANJING DRUM TOWER HOSPITAL
Application of ART (artesunate) as anti-leukemia-tumor drug
InactiveCN107050014AAchieve healingActivate growthOrganic active ingredientsAntineoplastic agentsAbnormal tissue growthIntraperitoneal route
The invention provides an application of ART (artesunate) as an anti-leukemia-tumor drug and relates to the field of medical health. ART is taken as a chemotherapeutic drug with targeted inhibition of STAT3 for leukemia tumor. Expression level of STAT3 can be inhibited rapidly and effectively, so that leukemia treatment is realized, ART has a strong inhibition effect on THP-1 cell proliferation and can induce THP-1 apoptosis, and the fact that ART can remarkably reduce protein level of STAT3 and activate Caspase8 and Caspase3 protein simultaneously to induce apoptosis is further proved. Intraperitoneal injection of ART into a THP-1 cell transplantation tumor mouse model discovers that ART can obviously inhibit tumor growth and down-regulate the expression level of STAT3 in tumor tissue. Experiments prove that ART plays an anti-tumor effect on THP-1 by down-regulating expression of STAT3 and activating apoptotic proteins Caspase8 and Caspase3 simultaneously.
Owner:AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE
Liposome co-carrying CD73 antibody and doxorubicin and its preparation method and application
ActiveCN113440610BImproved biodistributionExert anti-tumor effectOrganic active ingredientsAntibody ingredientsPhospholipinLipofectamine
The present invention provides liposomes co-carrying CD73 antibody and doxorubicin and its preparation method and application, wherein, the liposomes co-carrying CD73 antibody and doxorubicin is a lipid core coated with doxorubicin, The CD73 antibody is modified outside the lipid core, and the CD73 antibody is modified on the surface of the lipid core by coupling to the phospholipid PEG active ester micelles. The liposomes co-carrying CD73 antibody and doxorubicin provided by the invention reduce the drug resistance and side effects of doxorubicin in the treatment of triple-negative breast cancer, improve the biodistribution of doxorubicin in the body, and increase the bioavailability , and reversed the immune microenvironment in the tumor of triple-negative breast cancer, turning it into a hot tumor, and achieved a better therapeutic effect on triple-negative breast cancer.
Owner:SHANDONG UNIV
Macrophage drug-loading preparation and preparation method thereof
ActiveCN109044991AMeet the encapsulation rate requirementsRelease stabilityMammal material medical ingredientsCancer antigen ingredientsTumor targetCell activity
The invention relates to a macrophage drug-loading preparation and a preparation method thereof. The preparation method for the macrophage drug-loading preparation comprises the following steps: (1) enabling an anti-tumor drug to be dissolved in a solvent, and preparing an anti-tumor drug solution; (2) enabling macrophages to be suspended in a glucose solution of which a mass percent is (5+ / -1)%,to obtain macrophage suspension; (3) adding the anti-tumor drug solution to the macrophage suspension, and uniformly mixing; and (4) after culturing for 1.5-3.5 hours, centrifuging, and collecting a cell precipitate, to obtain the macrophage drug-loading preparation. The macrophage drug-loading preparation is high in encapsulation efficiency, long in drug-loading cell activity duration time, capable of slowly releasing a drug, and has good tumor targeting and inhibiting effects.
Owner:SUN YAT SEN UNIV
MicroRNA (micro ribonucleic acid) for regulating gene expression of B7-H4 (a molecule of the B7 family)
InactiveCN102776192AInhibit bindingExert anti-tumor effectAntineoplastic agentsDNA/RNA fragmentationMicroRNAVersus gene
The invention discloses MicroRNA (micro ribonucleic acid) for regulating gene expression of B7-H4 (a molecule of the B7 family). The microRNA is nucleic acid, functional segment or variant including a sequence of 5'-UGAGAUGAAGCACUGUAGCUC-3'. The microRNA is miR-143. Performed in-vitro biological function tests show that hsa-miR-143 is capable of inhibiting molecular expression of the B7-H4 by bonding with 3'-UTR (untranslated regions) of the B7-H4 gene, and antitumor effect is achieved by regulating a signal path of the B7-H4 and / or expression and functions of the miR-143.
Owner:SUZHOU UNIV
Polyethylene-glycol-modification water-solubility tryptanthrin polymer derivative, preparing method thereof and application thereof
The invention discloses a polyethylene-glycol-modification water-solubility tryptanthrin polymer derivative, a preparing method thereof and an application thereof, and belongs to the technical field of drug preparing. The polyethylene-glycol-modification water-solubility tryptanthrin polymer derivative is prepared after tryptanthrin and modified polyethylene glycol are reacted or prepared after modified tryptanthrin and polyethylene glycol are reacted. By means of the prepared water-solubility tryptanthrin polymer derivative (a water-solubility tryptanthrin prodrug), the solubility of the tryptanthrin can be increased by 200-3,000 times; the content of the tryptanthrin in the prodrug is 1%-90%, the acid sensitivity (acid sensitivity hydrazone bond rupturing) characteristic is achieved, the tryptanthrin can be dissociated in the weak acid environment at the tumor portion and the inflammation portion, and therefore drug activity is developed; nano-micelle can be prepared from the tryptanthrin polymer derivative with a mixed solvent dialysis method, and nano-micelle can be formed after the tryptanthrin and PEG are dissolved into water in a certain proportion.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Composition having immunoregulatory activity as well as preparation and application thereof
InactiveCN106309507AImprove immunityPromote proliferationAlgae medical ingredientsImmunological disordersImmunocompetenceActive ingredient
The invention provides composition having an immunoregulatory activity, as well as a preparation and an application thereof. The composition comprises an active ingredient and optional auxiliary materials, and is characterized in that the active ingredient comprises seaweed or defatted seaweed and oyster shells or comprises an extract from extraction of the seaweed or defatted seaweed and the oyster shells. The seaweed and oyster shell composition has the technical effect of synergistic interaction on the effect of improving immunocompetence.
Owner:MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
MicroRNA (micro ribonucleic acid) for regulating gene expression of PTEN (phosphatase and tensin homolog)
The invention discloses microRNA (micro ribonucleic acid) for regulating gene expression of PTEN (phosphatase and tensin homolog). The microRNA is nucleic acid, functional segment or variant including a sequence of 5'-caaagugcucauagugcagguag-3'. The microRNA is miR-20b. In-vitro biological function tests show that hsa-miR-20b is capable of inhibiting molecular expression of the PTEN by bonding with 3'-UTR (untranslated regions) of the PTEN gene, and antitumor effect can be achieved by regulating a signal path of the PTEN and / or expression and functions of the miR-20b.
Owner:SUZHOU UNIV
Liposome co-loaded with CD73 antibody and adriamycin, and preparation method and application of liposome
ActiveCN113440610AImproved biodistributionExert anti-tumor effectOrganic active ingredientsAntibody ingredientsAntiendomysial antibodiesTherapeutic effect
The invention provides a liposome co-loaded with CD73 antibody and adriamycin, and a preparation method and application of the liposome. A lipid core coated with the adriamycin is arranged in the liposome co-loaded with the CD73 antibody and the adriamycin, the outside of the lipid core is modified with the CD73 antibody, and the CD73 antibody is coupled to a phospholipid PEG active ester micelle and then is modified on the surface of the lipid core. The lipidosome co-loaded with the CD73 antibody and the adriamycin reduces the drug resistance and the toxic and side effects of the adriamycin in treatment of the triple negative breast cancer, improves in-vivo biological distribution of the adriamycin, improves bioavailability, and turns an immune microenvironment in a triple negative breast cancer tumor, so that the triple negative breast cancer tumor is converted into a thermal tumor, and a relatively good treatment effect for the triple negative breast cancer is realized.
Owner:SHANDONG UNIV
Aptamer and upconversion nanoparticle modified copolymer as well as synthesis and application thereof
ActiveCN112608487ASafe and efficient treatmentGuaranteed deep penetrationPharmaceutical non-active ingredientsAntineoplastic agentsAptamerMethacrylate
The invention provides an Aptamer and upconversion nanoparticle modified copolymer as well as synthesis and application thereof. The Aptamer and up-conversion nanoparticle modified copolymer mainly comprises Aptamer, up-conversion nanoparticles and a poly(2-hydroxyethylmethacrylate)-cinnamic acid copolymer, and is prepared by the following steps: dissolving the poly(2-hydroxyethylmethacrylate)-cinnamic acid copolymer in DMSO, adding aminated up-conversion nanoparticles uniformly dispersed in DMSO to prepare the up-conversion nanoparticle modified copolymer. Polyethylene glycol with two ends modified by maleimide and Aptamer are dissolved in a TE buffer solution, and then the up-conversion nanoparticle modified copolymer is added to prepare the target product. The Aptamer and upconversion nanoparticle modified copolymer has no participation of small molecular cytotoxic drugs, can induce aggregation of tumor cell surface receptors under near-infrared irradiation, triggers an apoptosis signal path, and has good anti-tumor curative effects in vivo and in vitro.
Owner:ZHEJIANG UNIV
Applications of miR-133 micromolecular nucleic acid medicines in preparing medicines for resisting gastric cancer
InactiveCN106466486APrevent proliferationExert anti-tumor effectOrganic active ingredientsGenetic material ingredientsWilms' tumorTargeted therapy
The invention relates to the technical field of biomedicine, and provides novel medical applications of miRNA miR-133, in particular to the applications of miR-133 in targeted therapy of malignant tumor molecules. The invention further discloses applications of miR-133 in preparing medicines for resisting gastric cancer. The experiment proves that during the generating process of gastric cancer, the expression of miR-133 is obviously inhibited; the recovery of the expression of miR-133 can be realized in the manner that the proliferation of gastric cancer cells is inhibited by targeted anti-apoptosis molecules Mcl-1 and Bcl-xL, so that the anti-tumor effect is achieved. With the adoption of the technical scheme, a novel potential molecular target is provided for the clinical treatment of gastric cancer.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Flavone-ligustrazine compounds CH-X having selective anti-liver cancer effect, preparation method and applications thereof
ActiveCN110857295APromote apoptosisExert anti-tumor effectOrganic active ingredientsOrganic chemistryCancer cellTumor cells
The invention provides a preparation method of a class of flavone-ligustrazine series derivatives, and applications of the flavone-ligustrazine series derivatives in preparation of antitumor drugs. According to the invention, the compound has obvious inhibition activity on the growth of tumor cell lines (HepG-2, Bel-7402, MCF-7, HT-29 and Hela), and almost does not affect a human normal vascular endothelial cell (HUVEC-12) line, the antitumor activity of part of the compounds is similar to the antitumor activity of a positive drug cis-platinum; the compound CH-5 has high selectivity between tumors and between tumors and normal cell lines, and has the strongest inhibition effect on liver cancer (Bel-7402), wherein the IC50s of the compound to HepG-2, Bel-7402, HT-29, MCF-7 and Hela respectively are 17.31+ / -0.47 [mu]M, 10.74+ / -1.12 [mu]M, 31.88+ / -1.96 [mu]M, 29.79+ / -2.18 [mu]M and 25.11+ / -1.80 [mu]M; and the compound CH-5 has no killing effect on HUVEC-12 cells while inhibiting cancer cells, and shows a certain proliferation promoting activity.
Owner:薪火炙药(北京)科技有限公司
Small RNA used for regulating expression of B7-H2 gene
InactiveCN102787117ABiologically activeInhibit expressionDNA/RNA fragmentationSignalling pathwaysVersus gene
The invention discloses a small RNA used for regulating expression of the B7-H2 gene. The small RNA is nucleic acid or a functional fragment or variant comprising the following sequence: 5'-cagugcaaugaugaaagggcau-3' and is miR-130b. According to results of in vitro biological function experiments carried out by the inventor, hsa-miR-130b can bind with 3'-UTR of the B7-H2 gene, thereby inhibiting expression of B7-H2 molecules; and an antitumor effect is exerted through regulation the expression and functions of B7-H2 signaling pathways and / or miR-130b.
Owner:SUZHOU UNIV
Water-soluble tryptanthrin polymer derivative modified by polyethylene glycol, preparation method and application thereof
ActiveCN105418909BImprove solubilityGood water solubilityAntipyreticAnalgesicsPolymer scienceTryptanthrine
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Application of thiourea molecule in preparation of antitumor drugs
ActiveCN105582002AReduce the effective copper concentrationNo toxicityAmide active ingredientsAntineoplastic agentsCarbon numberThiourea
The invention discloses application of a thiourea molecule in preparation of antitumor drugs. The structural formula of the thiourea molecule is selected from formula I to formula IV, wherein R1, R2 and R3 are independently selected from hydrogen, alkyl with a carbon number of 1-10, aryl or a heteroatom group containing N, O and S. The invention provides new application of the thiourea molecule, specifically in preparation of anticancer drugs. The thiourea molecule is adopted as the anti-cancer drug, or is used as the active ingredient for preparation of pharmaceutical preparations, the antitumor drugs show very low cytotoxicity to human lung adenocarcinoma cells (A549), human breast cancer cells (BCap-37), human oral epidermoid carcinoma cells (KB), human lung fibroblast (HFL1) and human bronchial epithelial cells (BEAS-2B), but has very good antitumor effect at the animal level. (formula I, formula II, formula III, and formula IV).
Owner:杭州墨丘利生物医药科技有限公司
A drug betaine conjugate, its pharmaceutical composition and application
ActiveCN104368011BHas anti-tumor effectExtended release half-lifePharmaceutical non-active ingredientsAntineoplastic agentsBetaineMedicinal chemistry
The invention discloses a pharmaceutical betaine conjugate and a pharmaceutical composition and an application thereof. The pharmaceutical composition contains the pharmaceutical betaine conjugate or a pharmaceutic composition composed of the pharmaceutical betaine conjugate and a pharmacologically acceptable carrier and is made into liquid preparations, solid preparations, semi-solid preparations, capsules, granules, gels and injections. The pharmaceutical composition is of liposomal nano-particles made of the pharmaceutical betaine conjugate or the composition of the pharmaceutical betaine conjugate and auxiliaries, to be specific, 10-100nm in particle size. The pharmaceutical betaine conjugate and the liposomal nano-particles thereof can serve as the liquid preparations, the solid preparations, the semi-solid preparations, sterilization preparations and sterile preparations and are low in toxicity and applicable to various tumor efficient treatments.
Owner:SOUTHEAST UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com